PPARδ agonist 9

• UNSPSC Description:

  PPARδ agonist 9 (compound 21) is a PPARδ agonist (EC50: 3.6 nM). PPARδ agonist 9 has in vivo efficacy, reducing serum levels of MCP-1 in mice and significantly inhibiting atherosclerosis progression in the LDLr-KO model (inhibition rate: 50-60%)[1].

• Target Antigen:

  PPAR

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage;Metabolic Enzyme/Protease;Vitamin D Related/Nuclear Receptor

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/pparδ-agonist-9.html

• Solubility:

  10 mM in DMSO

• Smiles:

  ClC1=CC(CC(O)=O)=CC(OCCC2(N3CCCC3)CCN(C4=NC5=CC=C(N=C5S4)C(F)(F)F)CC2)=C1

• Molecular Weight:

  569.04

• References & Citations:

  [1]Kato T, et al. Design, Synthesis, and Anti-Inflammatory Evaluation of a Novel PPARδ Agonist with a 4-(1-Pyrrolidinyl)piperidine Structure. J Med Chem. 2023 Aug 24;66(16):11428-11446..

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  928023-21-6